Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 3Sturge-Weber Syndrome 2Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Lennox Gastaut Syndrome 1Glioblastoma 1Epilepsy 1Epilepsies, Myoclonic 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Breast Neoplasms 1Arthralgia 1Anxiety Disorders 1

Interventions

Surveys and Questionnaires 4Therapeutics 2Psilocybin 2Ketamine 2Ultraviolet Therapy 1Self-Help Groups 1Relaxation Therapy 1Psychotherapy 1Psychosocial Intervention 1Propranolol 1Oxygen 1Nitrous Oxide 1Niacin 1N-Methyl-3,4-methylenedioxyamphetamine 1Minocycline 1Midazolam 1Melatonin 1Interviews as Topic 1Imagery, Psychotherapy 1Hormones 1Exercise Test 1Early Intervention, Educational 1Donepezil 1Dehydroepiandrosterone 1Counseling 1Cognitive Behavioral Therapy 1Cannabidiol 1Autogenic Training 1Anesthesia, Local 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anxiety Disorders × Cannabidiol × Clear all
NCT04482244 2025-07-29

RCT of CBD for Anxiety in Advanced Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 11 charts

Anxiety Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡